Oxigene, Inc.

Baylor University

Mateon Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

David J Chaplin

Kevin G Pinney

Klaus Edvardsen

Joseph Anthony Prezioso

Robert Ronald Kane

Charles Manly Garner, Iii

Mary Lynn Trawick

Jiangli Song

Kishore Kumar Gaddale Devanna

Erica Parker

Ronald W Pero

Zhi Chen

Vani P Mocharla

James Michael Dorsey

Mallinath Hadimani

Alan N Schwartz

Charles M Garner

Kimberly Perkins

Anupama Shirali

Bronwyn G Siim

Scott Young

Raymond Kessler

Usha Ghatak, Legal Representative

Usha R Ghatak, Legal Representative

Mark Wood

Jimmy Kessler

Anders Olsson

Tomas Ekberg

Phyllis Arthasary

Kumar Kishore Gaddale Devanna

Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.

Use of VDAS to enhance immunomodulating therapies against tumors

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful. 

Compositions and methods for inhibition of cathepsins

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

Functionalized stilbene derivatives as improved vascular targeting agents

This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.

Method for treating hematopoietic neoplasms

Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.

Compositions and methods with enhanced therapeutic activity

Chrome compounds have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

Chromene-containing compounds with anti-tubulin and vascular targeting activity

The present invention provides a method of using anti-hypertensive agents ('AHAs') to attenuate the transient increase in blood pressure observed in patients where Vascular Targeting Agents ('VTAs') are administered to treat diseases associated with malignant neovascularization. The invention also relates to pharmaceutical compositions comprising AHAs and VTAs, and to kits thereof.

Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents

A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

Tubulin binding ligands and corresponding prodrug constructs

Tubulin binding agents and corresponding prodrug constructs

Methods of killing tumor or cancer cells in human patients using an aryl N-substituted carboxamide having one or more aryl halo or one or more aromatic nitrogens, and/or acid addition salts thereof. The carboxamide may be an N-substituted nicotinamide or an N-substituted benzamide having such features, and may be used directly as a chemotherapeutic agent, or as a sensitizer for radiation or other chemotherapeutic agents. New compositions for such use include N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide, N-(2-diethylamino-ethyl) nicotinamide, and their acid addition salts, e.g. hydrochlorides.

Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use

Growing community of inventors

Watlington, United Kingdom

David J Chaplin